Search bioRxiv⌕ Search

Biology subjects

Sarfaraz, N.

Publications and source records attributed to Sarfaraz, N..

2 recordsLinked to original sources

Transcriptional Profiling of Commonly Used Liver Cancer Cell Lines Reveals Disease-Specific Modeling Potential and Authentication Concerns

Cell lines are essential tools for liver cancer research, yet their molecular fidelity to primary tumors remains incompletely characterized. Here we comprehensively evaluated transcriptomic similarities between commonly used liver cancer cell lines and primary tumor subtypes to guide optimal model selection. We analyzed RNA sequencing data from 541 samples spanning primary HCC, HPBL, CHOL, and FLC tumors, alongside 21 liver cancer cell lines and primary human hepatocytes. Through systematic variance analysis, we identified 2,523 highly variable genes distinguishing cancer subtypes and cell lines, then performed correlation analyses, unsupervised clustering, and pathway enrichment to assess molecular similarities. Molecular subtypes within each cancer type were identified through hierarchical clustering and characterized using pathway analysis. HepG2 cells showed strongest correlation with HPBL (r=0.62), confirming their hepatoblastoma origin despite frequent HCC misclassification. This correlation was driven by shared Wnt pathway dysregulation signatures. Huh7 cells best represented HCC, particularly the immune-modulatory, MYC-activated subtype with the highest median correlation. RBE cells optimally modeled CHOL, specifically the dedifferentiated, immune-evasive subtype. Several commonly used cell lines (LO2, SMMC-7721, MHCC97L) and specific publicly available samples demonstrated likely HeLa contamination. Primary human hepatocytes cultured under physioxic conditions better preserved liver-specific transcriptional programs compared to standard culture. No established cell line analyzed represented FLC strongly, identifying the need for a standard, available model. This transcriptomic framework provides evidence-based guidance for selecting appropriate liver cancer cell line models and highlights the critical need for rigorous cell line validation to improve experimental design and translational relevance of liver cancer research.

cancer biology↗

The Liver-Enriched Long Non-Coding RNA FAM99A Suppresses Tumorigenesis through Negative Regulation of Protein Synthesis

Primary liver cancer represents a significant global health burden, with limited therapeutic options for advanced disease. Long non-coding RNAs (lncRNAs) are increasingly found to play crucial roles in hepatic biology and disease progression. Here, we identify FAM99A as a highly liver-specific lncRNA that is systematically downregulated across liver malignancies, with reduced expression correlating with poor clinical outcomes. FAM99A exhibits remarkable tissue specificity with minimal expression outside the liver, and its levels rapidly decline during primary hepatocyte dedifferentiation in culture. Through isoform analysis, we establish FAM99A-203 as the predominant transcript in normal liver tissue and observe altered isoform distribution in liver cancers. Functionally, FAM99A overexpression inhibits anchorage-independent growth in liver cancer cell lines. Transcriptomic analysis reveals that FAM99A negatively regulates translation-related pathways in both liver cancer cells and primary hepatocytes. This is corroborated by protein synthesis assays showing that FAM99A overexpression substantially reduces global translation rates. Targeted RNase H-mediated extraction coupled with mass spectrometry identifies multiple components of the translation machinery as direct FAM99A binding partners, including eukaryotic translation initiation factors and RNA helicases involved in ribosome biogenesis. Clinical data analysis demonstrates significant inverse correlations between FAM99A expression and ribosomal protein genes in liver cancer patients. Additionally, hepatitis B virus appears to downregulate FAM99A expression, potentially contributing to its oncogenic properties. Our findings establish FAM99A as a liver-specific translational regulator that exerts tumor-suppressive effects by restraining protein synthesis rates, offering insights into hepatocarcinogenesis and the potential of FAM99A as both a biomarker and agent in new therapeutic avenues.

cancer biology↗